Biography for Nesa Nourmohammadi
Based out of the FierceMarkets Washington D.C. office, Nesa Nourmohammadi is a journalist whose work has appeared in The Washington Post, Humanize Magazine and the Indiana Daily Student, among other publications. Before joining FierceMarkets’ Life Sciences group as an associate editor in 2012, Nesa spent two years as a reporter for DC-area weekly newspaper The Gazette, covering local municipalities and writing a bi-weekly transportation column. Before graduating from Indiana University with a B.A. in journalism in 2009, she served as a web editorial intern for Marvel Comics in New York City. When she’s not working, she can be found playing football and softball in DC social sports leagues, enjoying video games, reading and traveling. Follow @NesaNFierce or email her at firstname.lastname@example.org.
Articles by Nesa Nourmohammadi
We set out to identify countries that offer the right mix of features for outsourcing and clinical work. But rather than focus on markets with well-established CRO operations, we looked for promising, upwardly mobile countries.
The North Carolina CRO announced that Chief Operating Officer Jamie Macdonald will assume the role of CEO beginning next year, marking one of three C-level promotions within the company.
While the study showed data quality from places like India, Eastern Europe and Latin America is on-par with Canada and the U.S., the study isn't perfect, ACRO admits.
Looking to keep cashing in on the growing outcomes data market, Philadelphia's ERT has acquired Invivodata. The deal will beef up ERT's electronic patient-recorded outcomes (ePRO) product portfolio as well as its reach in clinical outcome assessments (COAs).
ACRO is less than pleased with Toshiba, calling its latest TV ad offensive to clinical research and test subjects.
An 8-month-long study sponsored by Medidata Solutions has showed that up to 25% of clinical trial procedures administered to patients may be unnecessary, costing up to $5 billion of annual clinical trial costs.
As a Genetic Engineering & Biotechnology News story reveals, they are embracing strategic partnerships and adding capabilities to their arsenal to ensure long-term success.
Once finalized, Pernix hopes the acquisition will improve its profit margins on generics, while laying the foundation for developing future over-the-counter and prescription products, according to the pharma company
Valued at $49.4 million in terms of revenue in 2010 (a small but growing figure), the Argentine clinical trial market is forecast to grow at a compound annual growth rate of 9% between 2010 and 2015.
Nice Insight has released its own study showing what drug developers hope to do with their CRO and CMO partners.